Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284697617> ?p ?o ?g. }
- W4284697617 endingPage "1213" @default.
- W4284697617 startingPage "1207" @default.
- W4284697617 abstract "AZD7442 (Evusheld) is a combination of two human anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061). Route of administration is an important consideration to improve treatment access. We assessed pharmacokinetics (PKs) of AZD7442 absorption following 600 mg administered intramuscularly (i.m.) in the thigh compared with 300 mg intravenously (i.v.) in ambulatory adults with symptomatic COVID-19. PK analysis included 84 of 110 participants randomized to receive i.m. AZD7442 and 16 of 61 randomized to receive i.v. AZD7442. Serum was collected prior to AZD7442 administration and at 24 hours and 3, 7, and 14 days later. PK parameters were calculated using noncompartmental methods. Following 600 mg i.m., the geometric mean maximum concentration (Cmax) was 38.19 μg/mL (range: 17.30–60.80) and 37.33 μg/mL (range: 14.90–58.90) for tixagevimab and cilgavimab, respectively. Median observed time to maximum concentration (Tmax) was 7.1 and 7.0 days for tixagevimab and cilgavimab, respectively. Serum concentrations after i.m. dosing were similar to the i.v. dose (27–29 μg/mL each component) at 3 days. The area under the concentration-time curve (AUC)0–7d geometric mean ratio was 0.9 for i.m. vs. i.v. Participants with higher weight or body mass index were more likely to have lower concentrations with either route. Women appeared to have higher interparticipant variability in concentrations compared with men. The concentrations of tixagevimab and cilgavimab after administration i.m. to the thigh were similar to those achieved with i.v. after 3 days from dosing. Exposure in the i.m. group was 90% of i.v. over 7 days. Administration to the thigh can be considered to provide consistent mAb exposure and improve access." @default.
- W4284697617 created "2022-07-08" @default.
- W4284697617 creator A5004690007 @default.
- W4284697617 creator A5010897684 @default.
- W4284697617 creator A5011910289 @default.
- W4284697617 creator A5015601794 @default.
- W4284697617 creator A5017051528 @default.
- W4284697617 creator A5024029270 @default.
- W4284697617 creator A5024560316 @default.
- W4284697617 creator A5036716419 @default.
- W4284697617 creator A5041462486 @default.
- W4284697617 creator A5060710888 @default.
- W4284697617 creator A5084353681 @default.
- W4284697617 creator A5086686047 @default.
- W4284697617 creator A5087951804 @default.
- W4284697617 date "2022-07-26" @default.
- W4284697617 modified "2023-10-14" @default.
- W4284697617 title "Comparative Pharmacokinetics of Tixagevimab/Cilgavimab ( <scp>AZD7442</scp> ) Administered Intravenously Versus Intramuscularly in Symptomatic <scp>SARS‐CoV</scp> ‐2 Infection" @default.
- W4284697617 cites W2066738943 @default.
- W4284697617 cites W2140775698 @default.
- W4284697617 cites W2148106684 @default.
- W4284697617 cites W2156687094 @default.
- W4284697617 cites W2625688425 @default.
- W4284697617 cites W3013411029 @default.
- W4284697617 cites W3027630905 @default.
- W4284697617 cites W3111431752 @default.
- W4284697617 cites W3125712166 @default.
- W4284697617 cites W4200050840 @default.
- W4284697617 cites W4200051875 @default.
- W4284697617 cites W4200206478 @default.
- W4284697617 cites W4200272387 @default.
- W4284697617 cites W4200390169 @default.
- W4284697617 cites W4200536939 @default.
- W4284697617 cites W4205215807 @default.
- W4284697617 cites W4206984346 @default.
- W4284697617 cites W4220904663 @default.
- W4284697617 cites W4226004814 @default.
- W4284697617 cites W4226087845 @default.
- W4284697617 cites W4226236384 @default.
- W4284697617 cites W4226525051 @default.
- W4284697617 cites W4292315834 @default.
- W4284697617 doi "https://doi.org/10.1002/cpt.2706" @default.
- W4284697617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35797235" @default.
- W4284697617 hasPublicationYear "2022" @default.
- W4284697617 type Work @default.
- W4284697617 citedByCount "5" @default.
- W4284697617 countsByYear W42846976172022 @default.
- W4284697617 countsByYear W42846976172023 @default.
- W4284697617 crossrefType "journal-article" @default.
- W4284697617 hasAuthorship W4284697617A5004690007 @default.
- W4284697617 hasAuthorship W4284697617A5010897684 @default.
- W4284697617 hasAuthorship W4284697617A5011910289 @default.
- W4284697617 hasAuthorship W4284697617A5015601794 @default.
- W4284697617 hasAuthorship W4284697617A5017051528 @default.
- W4284697617 hasAuthorship W4284697617A5024029270 @default.
- W4284697617 hasAuthorship W4284697617A5024560316 @default.
- W4284697617 hasAuthorship W4284697617A5036716419 @default.
- W4284697617 hasAuthorship W4284697617A5041462486 @default.
- W4284697617 hasAuthorship W4284697617A5060710888 @default.
- W4284697617 hasAuthorship W4284697617A5084353681 @default.
- W4284697617 hasAuthorship W4284697617A5086686047 @default.
- W4284697617 hasAuthorship W4284697617A5087951804 @default.
- W4284697617 hasBestOaLocation W42846976172 @default.
- W4284697617 hasConcept C105795698 @default.
- W4284697617 hasConcept C112705442 @default.
- W4284697617 hasConcept C121332964 @default.
- W4284697617 hasConcept C125287762 @default.
- W4284697617 hasConcept C126322002 @default.
- W4284697617 hasConcept C140793950 @default.
- W4284697617 hasConcept C142724271 @default.
- W4284697617 hasConcept C204787440 @default.
- W4284697617 hasConcept C22979827 @default.
- W4284697617 hasConcept C24890656 @default.
- W4284697617 hasConcept C27081682 @default.
- W4284697617 hasConcept C2777288759 @default.
- W4284697617 hasConcept C33923547 @default.
- W4284697617 hasConcept C35785553 @default.
- W4284697617 hasConcept C40222840 @default.
- W4284697617 hasConcept C42219234 @default.
- W4284697617 hasConcept C71924100 @default.
- W4284697617 hasConcept C76318530 @default.
- W4284697617 hasConcept C86803240 @default.
- W4284697617 hasConcept C87813604 @default.
- W4284697617 hasConcept C98274493 @default.
- W4284697617 hasConceptScore W4284697617C105795698 @default.
- W4284697617 hasConceptScore W4284697617C112705442 @default.
- W4284697617 hasConceptScore W4284697617C121332964 @default.
- W4284697617 hasConceptScore W4284697617C125287762 @default.
- W4284697617 hasConceptScore W4284697617C126322002 @default.
- W4284697617 hasConceptScore W4284697617C140793950 @default.
- W4284697617 hasConceptScore W4284697617C142724271 @default.
- W4284697617 hasConceptScore W4284697617C204787440 @default.
- W4284697617 hasConceptScore W4284697617C22979827 @default.
- W4284697617 hasConceptScore W4284697617C24890656 @default.
- W4284697617 hasConceptScore W4284697617C27081682 @default.
- W4284697617 hasConceptScore W4284697617C2777288759 @default.
- W4284697617 hasConceptScore W4284697617C33923547 @default.
- W4284697617 hasConceptScore W4284697617C35785553 @default.